Based on the above results showing that GSK3β activity downregulates N1-ICD levels in CLL cells, we hypothesized that an inactive GSK3β contributed to sustain N1-ICD levels. This evidence concerns the gene GSK3B and B-cell chronic lymphocytic leukemia.